Rigel Pharmaceuticals, Inc. (RIGL)
- Previous Close
1.1000 - Open
1.1000 - Bid 1.0700 x 200
- Ask 1.1200 x 200
- Day's Range
1.0800 - 1.1250 - 52 Week Range
0.7100 - 1.9600 - Volume
351,535 - Avg. Volume
1,465,307 - Market Cap (intraday)
192.945M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1400 - Earnings Date Apr 30, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.57
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
www.rigel.comRecent News: RIGL
Performance Overview: RIGL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RIGL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RIGL
Valuation Measures
Market Cap
192.95M
Enterprise Value
196.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.64
Price/Book (mrq)
--
Enterprise Value/Revenue
1.68
Enterprise Value/EBITDA
-11.58
Financial Highlights
Profitability and Income Statement
Profit Margin
-21.67%
Return on Assets (ttm)
-10.73%
Return on Equity (ttm)
--
Revenue (ttm)
115.78M
Net Income Avi to Common (ttm)
-25.09M
Diluted EPS (ttm)
-0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
56.93M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.82M